Events and Presentations

Corporate Presentation
Pipeline Program Detail
Scientific & Medical Meetings
August 26, 2020
May 29, 2020
Source
A Phase 1 Study of mRNA-2752, a Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L, IL-23, and IL-36γ, for Intratumoral (iTu) Injection Alone and in Combination with Durvalumab
May 29, 2020
Source
A Phase 1 Study of mRNA-2752, a Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L, IL-23, and IL-36γ, for Intratumoral (iTu) Injection Alone and in Combination with Durvalumab
April 27, 2020
Source
A Phase 1/2, Open Label, Multicenter, Dose Escalation and Efficacy Study of mRNA 2416, A Lipid Nanoparticle Encapsulated mRNA Encoding Human OX40L, for Intratumoral Injection Alone or in Combination with Durvalumab for Patients with Advanced Malignancies
October 16, 2019
Source
mRNA Medicines to Enable Intracellular, Membrane-Bound, and Extracellular Secreted Therapeutics
October 2, 2019
Source
Phase 1 Trial of an mRNA-based Combination Vaccine Against hMPV and PIV3
June 1, 2019
Source
A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects With Resected Solid Tumors and in Combination With Pembrolizumab in Subjects With Unresectable Solid Tumors (Keynote-603)
June 1, 2019
Source
A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects With Resected Solid Tumors and in Combination With Pembrolizumab in Subjects With Unresectable Solid Tumors (Keynote-603)